doi: 10.3389/fvets.2022.860771 Received 23 January 2022 Accepted 03 March 2022 Published 06 April 2022 Volume 9 - 2022 Edited by Valeria Pasciu, University of Sassari, Italy Reviewed by Ignacio Contreras Sols, University of Sassari, Italy
It does not appear to interact negatively with other medications and has been well-tolerated across a wide range of doses in animal models
[PMC] Voronkov D, Stavrovskaya A, Gushchina A, Olshansky A (2021) Alterations in tanycytes and related cell populations of arcuate nucleus in streptozotocin-induced Alzheimer disease model
Tirzepatide represents a significant advancement in obesity and diabetes treatment, as it acts as a dual agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors[1]
However, as of now, the FDA has approved GLP-1 drugs only in the form of injections and pills 1 , 2 , and there are no approved form of GLP-1 transdermal (skin) patches which are in medical use
The primary endpoint, change in eGFR, was analysed using mixed-effects models